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Methods and Results: Transthoracic cardioversion was performed 85 * 187 days 
(range 7 minutes to 8 years) after the onset of atrial fibrillation in 315 patients who had a 
mean age of 6lil3 year?,. IRAF was defined as a recurrence of AF within 60 seconds 
after restoration of sinus rhythm. 
Results: IRAF occurred in 56% of patients when cardioversion was performed within 1 
hour of the onset of AF, compared to 12% of patients when cardioversion was performed 
after 24 hours of AF (p<O.OOl). The duration of AF was the only independent predictor of 
IRAF among the clinical variables of age, gender, structural heart disease, antiarrhythmic 
drug therapy, and cardioversion energy (p<O.Ol). 
Conclusions: IRAF is t-mare likely to occur when the duration of AF is cl hour than when 
the duration is ~24 hours. This observation has clinical implications for the most appropri- 
ate timing of cardioversion, particularly in patients who receive device therapy for AF. 
1015-16 Comparison of the Safety and Efficacy of Enoxaparin 
With Unfractionated Heparin and Phenprocoumon as 
Anticoagulation in Cardioversion of Nonvalvular Atrial 
Fibrillation 
Uwe Nixdorff Christoph Stellbhnk. Thomas Hofmann. Peter Hanrath, Walter Lehmacher, 
Andre Schmidt-Lucke. for the ACE Investigators, Medical Clinic II of Erlangen University, 
Erlangen. Germany 
In cardioversion (CV) of atrial fibrillation (AF), anticoagulation with UFH plus oral antico- 
agulant (OAC) is recommended. Conventional CV (OAC for 3 wks before and 4 wks after 
CV) or transesophageal echocardiography (TEE)-guided CV (i.v. UFH infusion plus 4 
wks of OAC, upon exclusion of left atrial (LA) thrombus) can be used. CV using i.v. UFH/ 
OAC is associated with extended hospitalizatton and stringent anticoagulation monitor- 
ing. Therefore LMWH may be a feasible alternative. 
Methods: Patients (n=496) with non-valvular AF lastina 48 h - 1 vear underwent convan- 
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1015-13 Intravenous Amiodarone in Cardioversion of New-Onset 
Atrial Fibrillation 
Jacek Cvbulski, Henryk Danielewicz, Piotr Kulakowski, Andrzej Budaj. Janusz 
Maciejewicz, Teresa Kawka-Urbanek, Leszek Ceremuzynski, Postgraduate Medical 
School, Warszawa. Poland 
Background: Paroxysmal atrial fibrillation (PAF) IS one of the most c~mmcm causes of 
hospital admissron. However, until now, no standard antiarrhythmic therapy has been 
accepted for pharmacological cardioversron of PAF. Amiodarone seems to be a promis- 
ing candidate, but only a few small, randomwad trials are available and the results are 
inconsitent. 
Aim of the study: To assess efficacy of intravenous amiodarone in cardioversion of 
PAF. 
Methods: 160 patients with PAF lasting less than 24 hours were randomly assigned 
(2:1) to amiodarone group (n=l06) receiving 5 mg/kg as a 30 min. iv infusion, followed by 
infusion of 10 mglkg during 20 hours and to the control grup (n=54). Both groups 
received 1000 ml of 10% glucose with 20 IU of rapid action insulin, 60 mEq of potassium 
chloride and 8 g of magnesium sulphate (GIKM) which is electrolyte supplementation 
routinely used in our department rn patients with PAF. Patients requiring emergency DC 
cardioversion were excluded. 
Results: Up to 8 hours after initiation of treatment 53 (50%) patients in amiodarone 
group and 14 (26%) patients in control group were converted to sinus rhythm (~~0.05). 
Twenty hours after initiation of the therapy sinus rhythm was restored in 88 (83%) 
patients in the amiodarone group and in 24 (44%) patients in the control group 
(p<o.oool). 
Conclusion: This study, which is one of the largest ever done on this subject, showed 
that amiodarone is effective in termination of PAF lasting less than 24 hours. It may be 
particularly useful in patients with left ventricular dysfunction, in whom class I antiarrhyth- 
mic agents are contraindicated. 
1015-14 DALTON Study: A Randomized Study Comparing 
Outpatient Dalteparin Administration to Inpatient 
Heparin for the Initiation of Anticoagulation in Atrial 
Fibrillation 
Francois Philippon, Gilles E. CSHara, Jean Champagne, Lyne Charbonneau, Helene 
Villeneuve, Louis Blier, Franck Mokn, Marcel Gilbert, Quebec Heart Institute, Sainte-Fey. 
PQ, Canada 
Atrial fibrillation (AF) patrents who need to be anticoagulated are often admitted to the 
hospital to receive IV heparin until the therapeutic INR has been reached. Some pts are 
sent home on warfarin alone with a potential risk for stroke. We conducted a prospective 
randomized trial compahng ah outpatient strategy using dalteparin (200 I.U./Kg, maxi- 
mum 18 000 I.U.) + warfarin (Da) to standard IV heparin + warfarin (He). A total of 192 
pts were randomized in a B(Da):l(He) ratio and 186 (Da:l42. He:44) completed the study 
(56 women, 130 men). The mean age was 70 * IO yrs and 44 % had a cardiovascular 
history and 50% had hypertension. 47% presented with paroxysmal AF, 50% with persis- 
tent AF and 3% were in chronic AF. The mean EF was 59 f 11% and mean left atrial size 
42 r 7 mm. Sinus rhythm was achieved spontaneously in 64 pts, 18 received ah antiar- 
rhythmic agent and 18 were electrically cardioverted. To achieve proper anticoagulation, 
the He group required a mean of 6.4 + 2.0 days of in-hospital IV heparin and the Da 
group 6.4 21.6 s/c injections. After 21 days, all pts were seen in clinic, 57 were rn AF, 5 in 
atrial flutter, 5 were paced and 119 were in sinus rhythm. Cost-effective and quality of life 
analysis were performed. No major complications or death were observed during the 
study period. Two thromboembotic complications were seen: one in the Da group with a 
pt presenting initially with a TIA the day before randomization (later recognized) and one 
pt in the He group where on day 21 a minor neurological deficit was noticed. Three pts in 
the He group presented with minor hemorrhagic complications (I ecchymosis and 2 
slight Hb drops). In the Da group, 12 pts had small ecchymosis at the injection site, 5 had 
minor epistaxis (one requiring medical anentton without transfusion or hospital admission 
in a pt with concomitant clopidogrel use), 4 had hematomas at the injection site (one 
required medical attention wrthout transfusion while receiving concomitant celecoxib). 
Conclusion: The use of dalteparin for the initiation of anticoagulation in pts with atrial 
fibrillation is a safe alternative to the conventional approach using IV heparin. It offers a 
cost-effective outpatient strategy that can alleviate the need for hospitalization. 
1015-15 Effect of Atrial Fibrillation Duration on Probability of 
Immediate Recurrence After Transthoracic 
Cardioversion 
Hakan Oral Mehmet Ozaydin. Christian Sticherling, Hiroshi Tada, Christoph Scharf, -I 
Aman Chugh, Frank Pelosi, Jr., Bradley P. Knight, Fred Morady, Unwersity of Michigan, 
Ann Arbor, Ml 
Background: An immediate recurrence of atria1 fibrillation (IRAF) appears to be mcwe 
crxnrrwn after early restoratron of sinus rhythm with ah implantable atrial defibrillator than 
after elective transthoracic cardiovenion, suggesting that the probability of IRAF may be 
related to the duration of AF. 
tional (group A, n=65) or TEE-guided CV (group B, n=431). Patients were randomized to 
either the LMWH enoxaoarfn (n=248). or to UFH plus the OAC phenoprocoumon 
(n=248). Patients without TEE:confirmed LA thrombus underwent ‘CV (group 81); 
patients with LA thrombus were anticoagulated for a further 3 wks, and underwent CV if 
repeat TEE did not detect LA thmmbus (group 82). The combined primary efficacy and 
safety endpoint was: stroke, transitory ischemic attacks, systemic embolism, death, and 
major bleeding events. 
Results: In the per-protocol population (n=428). there were no differences in the base- 
line characteristics of the enoxaparin (n=216) and UFH/OAC (n=212) groups. LA thrombi 
were detected in 9.7% of group B (n=370). Mean duration of treatment was 46+/-11 
days, (group A), 29+//-5 days (group Bl), and 46+/-15 days (group 82). Successful CV 
was achieved in 70.8% (303/428 patients): 66.2% (143/216) for enoxaparin and 75.5% 
(1601212) for UFHIOAC, respectively (p=O.O43, explorative). At the end of treatment, 
sinus rhythm was still present in 70.8% (214/303 patients) of successfully cardioverted 
patients: 67.1% (96/143) for enoxaparin and 73.8% (118/160) for UFHIOAC, respectively 
(p=O.21, explorative). Incidence of the primary endpoint was 3.2% (7/216) for enoxaparin 
vs 5.6% (12/212) for UFH/OAC (p=O.O17. confirmatory for equivalence with delta=2%). 
Conclusions: Enoxaparin shows non-inferior efficacy and safety to UFH/OAC in CV of 
AF, and may be preferred due to its reproducibility of anticoagulative effect and mare 
convenient S.C. administration. 
1015-17 Brain Natriuretic Peptide Levels Predict Successful 
Cardioversion and Rhythm Maintenance in Patients 
With Chronic Atrial Fibrillation 
Luis Beck-da-Silva, Adolfo de Bold, Margaret Fraser, Kathryn Williams, Chrrstine 
Struthers, Kayvan Abaiian, Haissam Haddad, University of Ottawa Heart Institute, 
Ottawa, ON, Canada 
Background: Brain natriuretic Peptide (BNP) is released from the heart by hemodynami- 
caky induced muscle stretch. Patients with atrial fibrillation have higher levels of BNP 
than controls in sinus rhythm. The aim of this study is to assess the usefulness of BNP as 
a predictor of successful cardioversion in patients with chronic atrial fibrillation. 
Method?.: We enrolled 20 patients undergoing cardioversion for chronic atrial fibrillation. 
BNP levels were measured prior, 30 min. and two weeks after electric cardioversion. 
Baseline echocardiograms and 12.lead electrocardiogram were obtained from all 
patients. Patients with valvular disease, previous mitral valve surgery or moderate to 
severe left ventricular dysfunction were excluded. 
Results: The mean BNP level and the mean heart rate were significantly higher before 
cardioversion than 30 min after (218 * 176 versus 194 f 196 pglml, p=O.O57; 80 f 22 
versus 56 * 11 pglml, p=O.OOOS) respectively. Patients’ mean ejection fraction was 55 + 
11%. Patients who reverted back to atrial fibrillation after two weeks had baseline BNP of 
260*13 pglml, while those who continued to be in sinus rhythm for two weeks had base- 
line BNP of 149*124 pg/ml, p=O.O27. No correlation was found between left atrial size 
and BNP levels. Left atrial size did not predict successful cardioversion, although most of 
the patients had mild left atrial dilatation (left atrial diameter = 4.6 * 0.6 cm) 
Conclusion: In patients with chronic atrial fibrillation BNP levels may predict successful 
cardioversion and maintenance of sinus rhythm two weeks after cardioversion. 
1015-18 Highly Sensitive C-Reactive Protein Level Predicts 
Recurrence of Atrial Fibrillation After Cardioversion in 
Patients on Antiarrhythmic Drugs 
Oussama Wazni, Nassir F. Marrouche. David Martin, Mostafasahin Shaaraoui, Walid 
Saliba. Eduardo Saad. Mandeeo Bharaava. Aleiandro Perez-Luaones, Andrea Natale, 
The Cleveland Clinic Foundation, Cl&eland, OH 
C-Reactive Protein (CRP) is a sensitive marker of systemtc rnflammation. Chronic eleva- 
tions of baseline CRP is a marker of low level systemic inflammation and has been used 
to predict increased risk for future myocardial infarction and stroke. Recently CRP levels 
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have also been shown to be elevated in patients with non-postoperative atrial arrhyth- 
mias, specifically atrial fibrillation (AF). We postulated that a high CRP level would predict 
AF recurrence in patients on antiarrhylhmic drugs (AAD). Methods and results: One hun- 
dred and fifty seven patients who had undergone direct current cardioversion for AF 
between November 2001 and June 2002 were identified (Tablel). All had CRP levels 
drawn prior to the procedure. All these patients had been on AAD prior to and following 
cardioversion. All patients were followed in our out patient clinic.109 patients had recur- 
rence of AF and 48 patients did not have recurrence of AF and responded to AAD. Using 
the Mann-Whitney nonparametric test the mean hsCRP level in the group with recur- 
rence was 0.642 which was statistically higher than the group with no recurrence 0.264 
(p-valuec0.001). Only left ventricular ejection fraction (LVEF) was related to hsCRP in 
multivariate analysis, however LVEF was not statistically different between both groups. 
The odds ratio of developing recurrence was 9 with every 0.5 unit increase over 0.554 (p- 
value<0.001). 
RRR=25%; p=O.57) in DDD-RV, 44% (4/9; RRR=BO%: p&1.13) in DDD-LV and 22% (2/9; 
RRR=75%; p=O.O18) in DDD-BiV. Conclusion: BiVP improves repolarization properties 
as measured by a reduction of TWA, thus contnbuting to the reduction of ventricular 
arrhythmias through this novel mechanism. 
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Conclusion: CRP levels predict recurrence AF in patients on AAD. This may help in risk 
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Wavelet Analysis of Heart Rate Variability Preceding 
Ventricular Arrhvthmias Retrieved From lmolantable 
Cardioverter Dafibrillators in Patients WithMyocardial 
Infarction 
Haran Burri Philippe Chevalier, Mohammad Awl, Paul Rub&, Jocelyne Fayn, Gilbert -3 
Kirkorian, Jean-Yves Le Heuzey, Paul Touboul, H6pital Louis Pradel. Lyon, France, 
H6pital Europ&en Georges Pompidou, Paris, France 
Background: Wavelet transform &VT) is well adapted for analyzing non-stationary sig- 
nals such as heart rate recordings. Changes in autonomic tone leading to ventricular 
arrhythmias may be studied by heart rate variability (HRV). Analysis at different scales by 
Wl can separate High Frequency (HF) from Low-Frequency (LF) signals. Instantaneous 
HF components reflect vagal activity, while LF components are under the influence of 
both sympathetic and parasympathetic tone. Thus, an increased LF/HF ratio may indi- 
cate either increased svmoathetic activitv or decreased vaaal tons. 
Methods: 42 patients (39 males, age 64+8 years) with a history of myocardial infarction 
imolanted with a Biotronik@ Phvlax XM or Microohvlax defibrillator (with an extended 
memory) were included. Each patient required electrical therapy for at least one episode 
of ventricular arrhythmia. RR intervals preceding events were retrieved from the device, 
and HRV studied by WT. 
Results: 117 episodes of ventricular arrhythmia(cycle length 35&22ms) were retrieved. 
LF/HF showed a significant increase dunng the 5 minutes preceding arrhythmia onset. 
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Conclusion: Analysis of HRV by WT shows evidence of increased sympathetic tone or 
parasympathettc withdrawal just before the onset of ventricular arrhythmias. 
1016-8 Does Biventricular Pacing Decrease the Incidence of 
Microvolt T-Wave Alternans? 
Ravmond C. Leunq. Sajad Gulamhusein, Alberta Van Schaik, Katherine Kavanagh, 
University of Alberta, Edmonton, AB, Canada 
Background: Biventricular pacing (BiVP) improves symptoms and hemodynamics in 
heart failure patients with ventricular conduction delay. Controversy exists as to why a 
significant reduction of ventricular arrhythmia was observed in patients with BiVP. Pres- 
ence of microvolt T-wave alternans (TWA) during rapid atrial pacing is independently 
predictive of ventricular arrhythmic events. We hypothesize that BiVP reduces ventricular 
arrhythmias by repolarization resynchronization as measured by a reduction of TWA. 
Methods: Patients (n=13) with permanent BiVP were studled. TWA were measured by 
spectral method using Heartwave system (Cambridge Heart) at rapid atrial (AAI) and var- 
ious ventricular (DDD) pacing modes. TWA were interpreted by standard protocol. 
Results: Four patients were excluded due to AV block at cl05 bpm. The results of the 
remaining 9 patients are shown below. In AAI pacing, 8 of the 9 patients (89%) have pos- 
itive TWA. Comparatively, frequency of positive TWA was reduced to 67% (619; 
1016-g Infarct Morphology Identifies Patients With Substrate 
for Ventricular Tachycardia 
David Belle David S. Fieno. F. Scott Per&s, Gina K. Song, Andrea Wesson, Rod -I 
Passman, Alan Kadish, Jeffrey Goldberger, Northwestern University Feinberg School of 
Medicine, Chicago, IL 
To evaluate whether infarct morphology identifies patients (pts) with substrate for induc- 
ible monomorphic ventricular tachycardia (MVT), 48 pts (age 6Oill years, 56% male) 
with coronary artery disease undergoing electrophysiologic studies (EPS) had tine and 
contrast-enhanced (gadolinium) MRI. Planimetry of the contrast images was used to 
measure infarct mass and surface area by two readers blinded to EPS results. 
Results: 21 (44%) pts had no inducible ventricular arrhythmias (No VT). 18 (37%) pts had 
inducible MVT, cycle length 273+49 ms, and 9 (19%) pts had inducible polymorphic VT 
or ventricular fibrillation (PVTNF). Table shows MRI results (in table, * = P&lt;0.005 vs 
No VT). There were no differences in ejection fraction (EF) among the three groups, but 
pts with MVT had larger infarcts. By linear regression, infarct size correlates negatively 
with EF (R2 0.21 to 0.27, p&lt:O.OOl). Infarct size was a better discriminant of inducible 
MVT than EF. The findtngs for PVTNF wars intermediate between those for No VT and 
MVT, consistent with the nonspecific nature of this induced arrhythmia. Transmural inf- 
arct, aneurysms, and infarct location did not discriminate between pts with inducible MVT 
and pts with No VT. 
MRI Findings 
Infarct mass Infarct mass as % Of Infarct Surface Area EF (%) 
(9) LV (mm2) 
NOVT 2&5 14*3 9289*1403 35*3 
MVT 49*5 26i3 * 17201+1531 * 28+2 
PVTNF 36+7 20*3 11482+2210 * 34+6 
Conclusion: Infarct size is a better identifier of patients who have MVT than EF. As all 
current clinically used risk stratification strategies are based on EF, further evaluation of 
infarct morphology characterization by cardiac MRI is warranted. 
1016-10 Frequency of Implantable Cardioverter Fibrillator 
Discharges in New York Following the World Trade 
Center Attack 
Avsha Arshad. Marcin Kowalski. Atul Kukar, Valentin Suma, Margot E. Vloka, Frederick 
A. Ehlert, Bengt Herweg, Jacqueline E. Donnelly, Julie Philip, George Reed, Alan 
Rozanski, Jonathan S. Steinberg, St. Luke’s_Roosevelt Hospital Center and Columbia 
University College of Physicians and Surgeons, New York, NY, University of 
Massachusetts Medical School, Worcester, MA 
Background: We have recently described an increase in the ICD discharge rate of pati- 
etns in the New York metropolitan area following the World Trade Center (WTC) attack 
on 9/l l/01. In our cohort of 200 patients there was a 2.3-fold increase in risk in the 30 
days after 9/l 1 versus the 30 days before. We sought to evaluate the ICD discharge rate 
in this population over an 8 month observation period and to detenine when the 
increased rate of discharges returned to pre 9/l 1 levels. 
Methods: To determine the pattern of daily arrhythmic events from 5/l l/O1 to l/10/02, 
triggering ICD discharges over the 8 month time period, a logistic model and a general- 
ized estimating equation approach to account for within subject correlation were 
employed. 
Results: The incidence of ICD activation for ventricular tachvarrhvthmias for Mav , , 
through July 2001 was 2.1-4.4% and for October through December 2001 was 2.2.3.2%, 
versus 8% for Seotember 2001. Looistic rearession model identified the 30 dav oeriod _ _ , 
following 9/l 1 as statistically different (p=O.O038) than the other 30 day intervals. (see 
figure) 
